- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05323253
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective multicenter, pivotal, single arm, open label clinical study to assess the efficacy and safety of intratumoral Alpha DaRT-224 for the treatment of patients with recurrent cutaneous squamous cell carcinoma.
The "Diffusing Alpha-emitter Radiation Therapy (DaRT)", based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life), is described in this study. These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. DaRT seeds will be inserted into recurrent Squamous Cell Carcinoma (SCC) tumors and will be removed following 14-21 days.
The Objective Response Rate (ORR) will be determined based on the confirmed Best Overall Response (BOR) following DaRT insertion. Duration of Response (DOR) will be assessed for up to 6 months from initial response is documented. Safety will be assessed based on the cumulative incidence rate, severity and outcome of device related Adverse Events (AEs). Classification of AEs will be done according to CTCAE v5.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Liron Dimnik
- Phone Number: +972-2-3737-210
- Email: LironD@alphatau.com
Study Contact Backup
- Name: Aviya Hoida
- Phone Number: +972-2-3737-210
- Email: aviyah@alphatau.com
Study Locations
-
-
-
Haifa, Israel
- Recruiting
- Rambam Medical Center
-
Contact:
- Tomer Charas, MD
- Phone Number: +972502062073
- Email: t_charas@rambam.health.gov.il
-
Jerusalem, Israel, 9777605
- Recruiting
- Hadassah Medical Center
-
Contact:
- Aron Popovtzer, MD
- Phone Number: 972-2-6776709
- Email: aron@hadassah.org.il
-
Petah tikva, Israel
- Recruiting
- Belinson-Rabin Medical Center
-
Contact:
- Elisha Fredman, MD
- Phone Number: +972-538299243
- Email: elishafre@clalit.org.il
-
Ramat Gan, Israel
- Recruiting
- Sheba Medical Center
-
Contact:
- Iris Gluck, MD
- Phone Number: +97252-6669142
- Email: iris.gluck@sheba.health.gov.il
-
Contact:
- Shlomit Shamir Druskin
- Phone Number: 0507327830
- Email: Shlomit.ShamirDruskin@sheba.health.gov.il
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner Health MD Anderson Phoenix
-
Contact:
- Michael Samuels, MD
- Phone Number: 305-213-8550
- Email: michael.samuels2@bannerhealth.com
-
Contact:
- Pamela Urban
- Email: Pamela.Urban@bannerhealth.com
-
Phoenix, Arizona, United States, 85004
- Recruiting
- Dignity Health Cancer Institute
-
Contact:
- Shyamal Patel, MD
- Email: shyamal.patel@commonspirit.org
-
Contact:
- Rebecca Pena
- Phone Number: 602-406-0354
- Email: rebecca.pena900@commonspirit.org
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Withdrawn
- University of Arkansas
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA
-
Contact:
- Albert Chang, MD
- Phone Number: 617-935-9275
- Email: ajchang@mednet.ucla.edu
-
Contact:
- Jackie Hernandez
- Phone Number: 310-267-8991
- Email: JHernandez@mednet.ucla.edu
-
Los Angeles, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Yi Jen Chen, MD
- Phone Number: 626-922-7657
- Email: yichen@coh.org
-
Contact:
- Hesham Mahmoud
- Email: hmahmoud@coh.org
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Recruiting
- Boca Raton Regional Hospital
-
Contact:
- Ileana Vargas
- Email: ivargas@baptisthealth.net
-
Contact:
- Michael E Kasper, MD
- Phone Number: 561-213-6465
- Email: mkasper@baptisthealth.net
-
Miami, Florida, United States, 33101
- Recruiting
- University of Miami
-
Contact:
- Matthew Abramowitz, MD
- Phone Number: 305-781-6555
- Email: mabramowitz@med.miami.edu
-
Contact:
- Zuzel Rodrigues
- Phone Number: +13052430124
- Email: z.rodriguez1@med.miami.edu
-
Miami, Florida, United States, 33176
- Recruiting
- Baptist Health South Florida MCI
-
Contact:
- Noah S Kalman, MD
- Phone Number: 203-645-0185
- Email: noahk@baptisthealth.net
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Evan Wuthrick, MD
- Phone Number: 631-807-4596
- Email: evan.wuthrick@moffitt.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory University
-
Contact:
- Zachary Buchwald, MD
- Email: Zbuchwa@emory.edu
-
Contact:
- Stacie Hitchcook
- Email: stitch2@emory.edu
-
-
Iowa
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Unitypoint Health
-
Contact:
- Arshin Sheybani, MD
- Email: arshin.sheybani@unitypoint.org
-
Contact:
- Sheila Young
- Phone Number: (515) 241-3305
- Email: syoung@iora.org
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Contact:
- Mauricio Gamez, MD
- Phone Number: 215-990-6189
- Email: gamezharo.mauricio@mayo.edu
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Recruiting
- Holy Name Medical Center
-
Contact:
- Benjamin Rosenbluth, MD
- Phone Number: 201-541-5900
- Email: brosenbluth@holyname.org
-
Contact:
- Lydia M Ko
- Phone Number: +1201-530-7934
- Email: lko@holyname.org
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Recruiting
- New Mexico Cancer Center
-
Contact:
- Gregg E.Franklin, MD
- Phone Number: 505-235-7245
- Email: greggef@nmohc.com
-
Contact:
- Sarah Tellez
- Phone Number: (505)8144923
- Email: saraht@nmohc.com
-
-
New York
-
Cooperstown, New York, United States, 13326
- Recruiting
- Bassett Healthcare Network
-
Contact:
- Timothy Korytko, MD
- Phone Number: 646-401-2002
- Email: timothy.korytko@bassett.org
-
Contact:
- Katelyn Tessier
- Email: katelyn.tessier@bassett.org
-
Queens, New York, United States, 11375
- Recruiting
- Northwell Health
-
Contact:
- Bhupesh Parashar, MD
- Phone Number: 347-613-0760
- Email: bparashar@northwell.edu
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Christipher Barker, MD
- Phone Number: 646-400-1452
- Email: barkerc@mskcc.org
-
Contact:
- Ming Lian
- Email: lianm@mskcc.org
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Medical Center
-
Contact:
- Joshua Palmer, MD
- Phone Number: 917-601-3414
- Email: joshua.palmer@osumc.edu
-
Contact:
- Sujith Baliga
- Phone Number: (706)4056429
- Email: sujith.baliga@osumc.edu
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- West Cancer Center
-
Contact:
- Noam Vanderwalde, MD
- Phone Number: 901-484-9172
- Email: nvanderwalde@westclinic.com
-
Contact:
- Catherine Morningstar
- Phone Number: +1901-484-3089
- Email: cmorningstar@westclinic.com
-
-
Texas
-
Houston, Texas, United States, 77089
- Recruiting
- University Cancer & Diagnostic Center
-
Contact:
- Mark D'Andrea, MD
- Phone Number: 713-474-1414
- Email: mmmeead@aol.com
-
Contact:
- Jo Ann Ramirez
- Phone Number: 713-474-1414
- Email: jramirez@gulfcoastcc.com
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia Health System
-
Contact:
- Christopher McLaughlin, MD
- Phone Number: 434-243-8885
- Email: cm9rs@hscmail.mcc.virginia.edu
-
Contact:
- Song Wood
- Email: stw2g@hscmail.mcc.virginia.edu
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Recruiting
- Dermatology of Seattle and Bellevue
-
Contact:
- Elie Levy, MD
- Phone Number: 425-455-5111
- Email: elevy@dermatologyseattle.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with recurrent cutaneous SCC histologically confirmed who have failed at least first line standard of care therapy who are not indicated for surgery and standard radiation therapy, or non alpha radiation brachytherapy technologies, and for whom no curative systemic treatment is available
- Central histopathological confirmation within 6 months of enrollment provided no tumor treatment occurred between the biopsy and enrollment
- Measurable disease according to RECIST v 1.1.
- Ability to undergo a CT scan
- Tumor size ≤7 cm, at the longest diameter.
- Single lesion per subject.
- Targeted lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds.Targets will be deemed technically amenable for complete coverage if there are entry and exit vectors for placement that are not hindered by bone or major vessels or other vital organs (eg. eye).
- Interstitial implant indication validated by multidisciplinary team.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
- Life expectancy ≥12 months.
- Subjects male/ female ≥18.
- Willing and have the ability to provide signed Informed Consent.
- Patients, male and female, with reproductive potential (including women who are menopausal for less than a year and not surgically sterilized), must practice acceptable effective methods of birth control, such as barrier methods, condom or diaphragm with spermicide or abstinence. Birth control should be continued for 3 months after the DaRT insertion visit.
- Women with childbearing potential must provide a negative pregnancy test during the screening period and up to V1, prior to the DaRT insertion procedure.
Blood tests values:
- Leucocytes ≥3000mm3,
- Absolute neutrophil count ≥1500mm3,
- Platelets ≥100,000 mm3,
- Total bilirubin ≤ 1.5xULN (upper limit of normal)
- Aspartate Aminotransferase (AST) ≤2.5xULN,
- Serum Glutamic-Oxaloacetic Transaminase (SGOT) ≤2.5xULN,
- Serum Glutamic-Pyruvic Transaminase (SGPT) ≤2.5xULN,
- Alkaline Phosphatase ≤2.5xULN.
- Creatinine ≤ 2.0xULN or Creatinine Clearance ≥60 ml/min.
- INR (International Normalized Ratio) or Prothrombin time ≤1.5xULN.
Exclusion Criteria:
- Distant or nodal metastatic disease (according to the TNM [tumor, nodes , and metastases] staging system - N+ or M1 patients are excluded).
- T4 disease or perineural spread of disease
- Previously untreated cutaneous SCC indicated for surgery or radiation.
- Mucosal, vulvar, anal and penile SCC.
- Inability to fully cover the entire volume with DaRT seeds
- Inability to place DaRT seeds into tumor due to inaccessibility by presence of bones or major vessels or vital organs
- Inability to undergo a CT scan
- Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
Patients receiving any of the following within 4 weeks of enrollment:
- Antineoplastic systemic chemotherapy or biological therapy
- Immunotherapy
- Investigational agents other than the study intervention
- Radiation therapy
- Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial.
- Longest tumor diameter >7 cm.
- Tumor with keratoacanthoma histology.
- Known hypersensitivity to any component of treatment.
- Clinically significant cardiovascular disease e.g., cardiac failure of New York Heart Association class III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, history of myocardial infarction in the last 12 months.
- Any medical or Psychiatric illness, which in the opinion of the investigator would compromise the patient's ability to tolerate treatment and to adhere to the clinical trial protocol.
- Serious medical comorbidities that, in the opinion of the investigator, may affect subject compliance and/or interpretation of treatment safety or effectiveness.
- High probability of protocol non-compliance (in opinion of investigator).
- Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry and for 3 months after the DaRT insertion visit.
- Breastfeeding or pregnant women
- Tattoos or other identifying marks which can not be adequately hidden on digital photos
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DaRT seeds
DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
Objective Response Rate (ORR) will be determined based on confirmed BOR following DaRT insertion.
|
DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: From Day 14 until 52 weeks
|
Objective Response Rate (ORR) of DaRT as treatment for Recurrent SCC established by the confirmed Best Overall Response (BOR), with confirmation at least 4 weeks after initial assessment
|
From Day 14 until 52 weeks
|
Duration of Response
Time Frame: 6 months from from first demonstration of CR or PR after Alpha DaRT seeds insertion.
|
Assess the Duration of Response (DOR) of DaRT as treatment for Recurrent SCC
|
6 months from from first demonstration of CR or PR after Alpha DaRT seeds insertion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: Up to 12 months after DaRT seed insertion
|
Determine Progression Free Survival (PFS) of SCC following DaRT treatment
|
Up to 12 months after DaRT seed insertion
|
Overall Survival
Time Frame: Up to 12 months following DaRT insertion
|
Assess Overall Survival (OS) of Recurrent SCC patients treated with DaRT
|
Up to 12 months following DaRT insertion
|
Time of Local Control
Time Frame: Up to 12 months following DaRT insertion
|
Local control of SCC following DaRT treatment is measured as the time from first recorded response (Complete Response/Partial Response/Stable Disease) to local recurrence up to 12 months or last follow up
|
Up to 12 months following DaRT insertion
|
Patients Quality of Life Assessment
Time Frame: On 14 days,12 weeks and 52 weeks following DaRT insertion
|
Assess patient reported health related quality of life (QOL) outcomes using the Skin Cancer Index (SCI) and Skindex-16 questionnaires
|
On 14 days,12 weeks and 52 weeks following DaRT insertion
|
DaRT-related Adverse Events
Time Frame: Up to 12 months following DaRT insertion
|
Assess the safety of the Alpha DaRT treatment, based on the cumulative incidence rate, severity and outcome of device related AEs.
Classification of AEs will be done according to CTCAE v5
|
Up to 12 months following DaRT insertion
|
Overall Duration of Response (O-DOR)
Time Frame: Up to 12 months following first reported response
|
O-DOR Defined as the time from first response (CR or PR) to the date of initial objectively documented progression or death due to any cause, whichever occurs first.
|
Up to 12 months following first reported response
|
User experience
Time Frame: On Day 0 (DaRT insertion) and Day 14 (+7) (DaRT removal)
|
Assess user experience as determined by questionnaire
|
On Day 0 (DaRT insertion) and Day 14 (+7) (DaRT removal)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTP-SCC-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Squamous Cell Carcinoma
-
Hyunseok Kang, MDNeoImmuneTechRecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
Regeneron PharmaceuticalsSanofiCompletedRecurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma NeckKorea, Republic of, United Kingdom
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditionsCanada
Clinical Trials on DaRT seeds
-
Alpha Tau Medical LTD.Not yet recruitingCarcinoma of the Vulva | Recurrent Carcinoma of the Vulva
-
Alpha Tau Medical LTD.Not yet recruitingNon-metastatic Prostate Cancer | Locally Recurrent Prostate CancerIsrael
-
Alpha Tau Medical LTD.RecruitingMalignant TumorIsrael
-
Alpha Tau Medical LTD.Not yet recruitingPancreatic Cancer | Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer
-
Alpha Tau Medical LTD.RecruitingSkin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue NeoplasmIsrael
-
Alpha Tau Medical LTD.Active, not recruitingSkin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue NeoplasmIsrael
-
Alpha Tau Medical LTD.CompletedSquamous Cell CarcinomaIsrael
-
Alpha Tau Medical LTD.RecruitingSkin Cancer | Mucosal Neoplasm of Oral Cavity | Soft Tissue NeoplasmIsrael
-
Alpha Tau Medical LTD.CompletedSkin Squamous Cell CarcinomaItaly
-
Sheba Medical CenterCompleted